Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;6(4):203-9.

Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial

W Decleer  1 , K Osmanagaoglu  1 , B Seynhave  2 , S Kolibianakis  3 , B Tarlatzis  3 , P Devroey
Affiliations

Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial

W Decleer et al. Facts Views Vis Obgyn. 2014.

Abstract

A prospective randomized controlled trial comparing two groups of ICSI (intra-cytoplasmatic sperm injection) patients with a different form of triggering the final oocyte maturation has been performed. All patients received an ovarian stimulation for in vitro fertilisation (IVF) using an antagonist protocol using recombinant-FSH -(rec-FSH) and Ganirelix. 120 Patients were randomized into two groups with similar clinical parameters. The first group had triggering with hCG, whereas the second group received a combination of hCG + GnRH agonist (Gonadotropin Releasing Hormone). As the primary endpoint, the number of metaphase II oocytes were analysed, the secondary endpoints were the number of cumulus oocyte complexes (COC), the number of fertilized oocytes, embryo morphology, pregnancy rate and the number of cryopreserved embryos. The mean number of MII oocytes in the hCG triggered group was 9.2 compared with 10.3 in the hCG-GnRH agonist group. There was no statistically significant difference in the number of COCs or pregnancy rates. However, the number of patients who received at least one embryo of excellent quality was significantly higher (p = 0.001) in the group with the combined triggering (45 out of 61 patients or 73.8%) versus the group with hCG triggering alone (28 out of 59 patients or 47.5%). The number of cryopreserved embryos was also higher in this group.

Keywords: Dual triggering; FSH surge; GnRH agonist triggering; GnRH antagonist; ICSI; IVF; final oocyte maturation; hCG triggering.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Graphic display of the evolution of FSH, LH, Estradiol and progesterone levels following triggering of final oocyte maturation (blue line: hCG group, red line: dual triggering group).
See this image and copyright information in PMC

References

    1. Albano C, Grimbizis G, Smitz J, et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril. 1998;70:357–359. - PubMed
    1. Devroey P, Aboulghar M, Garcia-Velasco J, et al. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod. 2009;24:764–774. - PubMed
    1. Devroey P, Polyzos N, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011;26:2593–2597. - PubMed
    1. DiLuigi A, Engmann L, Schmidt D, et al. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril. 2010;94:1111–1114. - PubMed
    1. Engmann L, Di Luigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertil Steril. 2008:84–91. - PubMed

LinkOut - more resources